Jill Leversage

Jill Leversage (board member) discloses dealings in Aurinia Pharmaceuticals Inc. to SEC (Form 4). Over a trading history stretching from 29 January 2021 to 21 November 2024, the count stands at 9 filings.

The open-market side counts 4 purchases for €72k alongside 2 sales for €80k. Taken together, the sales exceed the purchases by €7,947. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 2 share grants and 1 option exercise. 2024 to date brings no purchases and 1 sale.

The median purchase comes to €19k. Clusters matter here: 3 out of 4 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. For 4 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 25% of cases, with a median move of -24.0%. They describe history only and say nothing certain about the share price ahead.

The newest entry dates from 25 November 2024: a share grant, in Aurinia Pharmaceuticals Inc. The most recent open-market purchase was published on 15 December 2021, 1,791 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.